ChemicalBook > CAS DataBase List > Tofacitinib

Tofacitinib

Tofacitinib Structure
Tofacitinib
  • CAS No.477600-75-2
  • Chemical Name:Tofacitinib
  • CBNumber:CB0970901
  • Molecular Formula:C16H20N6O
  • Formula Weight:312.38
  • MOL File:477600-75-2.mol
Tofacitinib Property
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal word
  • Hazard statements
  • Precautionary statements
Tofacitinib Price More Price(35)
  • Brand: Usbiological
  • Product number: C7905-90
  • Product name : Tofacitinib
  • Purity: 
  • Packaging: 25mg
  • Price: $215
  • Updated: 2021/12/16
  • Buy: Buy
  • Brand: Biosynth Carbosynth
  • Product number: FT32555
  • Product name : Tofacitinib
  • Purity: 
  • Packaging: 500 mg
  • Price: $225
  • Updated: 2021/12/16
  • Buy: Buy
  • Brand: Activate Scientific
  • Product number: AS17628-A
  • Product name : Tofacitinib
  • Purity: 98%
  • Packaging: 1 g
  • Price: $250
  • Updated: 2021/12/16
  • Buy: Buy
  • Brand: Biosynth Carbosynth
  • Product number: FT32555
  • Product name : Tofacitinib
  • Purity: 
  • Packaging: 1 g
  • Price: $300
  • Updated: 2021/12/16
  • Buy: Buy
  • Brand: ChemScene
  • Product number: CS-0050
  • Product name : Tofacitinib
  • Purity: 99.96%
  • Packaging: 1g
  • Price: $330
  • Updated: 2021/12/16
  • Buy: Buy

Tofacitinib Chemical Properties,Usage,Production

  • Description In November 2012, the US FDA approved tofacitinib (also referred to as CP-690550) for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. Tofacitinib is the first small molecule kinase inhibitor approved for the treatment of RA. Tofacitinib is an inhibitor of the four subtypes of Janus kinase (JAK): JAK1, JAK2, JAK3, and Tyk2. The JAKs are intracellular, nonreceptor tyrosine kinases that play important roles in the signal transduction pathway of many cytokines (e.g., interleukins 2, 4, 7, 9, 15, and 21) and are involved in the propagation of inflammation in RA. Tofacitinib acts by inhibiting the phosphorylation and activation of signal transducers and activators of transcription (STATs), thereby suppressing the production of inflammatory mediators in joint tissue. At the enzyme level, tofacitinib inhibits JAKs 1, 2, 3, and Tyk2 with IC50s of 3.2, 4.1, 1.6, and 34 nM, respectively. At the cellular level, tofacitinib inhibits the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50s of 406, 56, and 1377 nM, respectively.
  • Chemical Properties Light Pink to Pale Orange Solid
  • Originator Pfizer (United States)
  • Uses CP-690550 is a pyrrolo[2,3-d]pyrimidine derivative, as Janus kinase inhibitor for treatment of rheumatoid arthritis
  • Definition ChEBI: A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely ctive rheumatoid arthritis.
  • Indications The JAK family includes four isoforms, JAK1, JAK2, JAK3, and tyrosine kinase (TYK2). Ruxolitinib (Jakafi(R), Incyte Corp.) was the first approved JAK inhibitor, which inhibits both JAK1 and JAK2, used for the treatment of different types of myelofibrosis. Tofacitinib (Xeljanz(R), Pfizer) was approved by FDA as a JAK3-selective inhibitor for the treatment of rheumatoid arthritis and is one of the only two FDA-approved kinase inhibitors for non-oncological indications.
  • brand name Xeljanz
  • Chemical Synthesis Commercially available aminopyridine 171 was reacted with dimethyl dicarbonate in the presence of potassium t-butoxide to give the methyl carbamate 172 in 87% yield. Hydrogenation of this carbamate 172 in the presence of 20 wt% of 5% Rh/C (JM type C101023-5) in acetic acid followed by reductive amination with benzaldehyde and sodium triacetoxy borohydride furnished the cis-benzyl protected piperidine 173 in 73% yield. Reduction of the methyl carbamate within 173 with lithium aluminum hydride (LAH) in THF gave the corresponding methyl amino piperidine which was isolated as the dihydrochloride salt 174 in 87% yield. Enantiomeric resolution of the methyl amino piperidine was achieved by freebasing the di-hydrochloride salt 174 with sodium hydroxide and then conversion to the di-toluol-L-tartaric acid salt followed by crystallization to give 175 in 42% yield and 98.6% ee. The enantioenriched tartrate salt 175 was then directly reacted with dichloride 176 (obtained from reaction of commercial 7H-pyrrolo[2,3-d]pyrimidine-2,4-diol (178) with phosphorous oxychloride) in the presence of potassium carbonate in water to give the coupled product 177 in essentially quantitative yield. Hydrogenation of intermediate 177 with DeGussa’s catalyst triggered concomitant debenzylation and chloride removal, and this was followed by installation of the cyanoacetate group and subsequent treatment with citric acid to provide tofacitinib citrate (XXVII) in 90% yield.

Tofacitinib Preparation Products And Raw materials
Raw materials
Preparation Products
Global(358)Suppliers
  • Supplier:
    Shenzhen Shengda Pharma Limited
  • Tel:+86-755-85269922
  • Fax:WeChat:shengdapharm
  • Email:sales@shengdapharm.com
  • Country:CHINA
  • ProdList:310
  • Advantage:58
  • Supplier:
    Capot Chemical Co.,Ltd.
  • Tel:+86(0)13336195806 +86-571-85586718
  • Fax:+86-571-85864795
  • Email:sales@capotchem.com
  • Country:China
  • ProdList:20012
  • Advantage:60
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:0371-55170693
  • Fax:0371-55170693
  • Email:info@tianfuchem.com
  • Country:China
  • ProdList:22607
  • Advantage:55
  • Supplier:
    Hangzhou FandaChem Co.,Ltd.
  • Tel:008615858145714
  • Fax:+86-571-56059825
  • Email:fandachem@gmail.com
  • Country:China
  • ProdList:9165
  • Advantage:55
  • Supplier:
    ATK CHEMICAL COMPANY LIMITED
  • Tel:+86 21 5161 9050/ 5187 7795
  • Fax:+86 21 5161 9052/ 5187 7796
  • Email:ivan@atkchemical.com
  • Country:CHINA
  • ProdList:26781
  • Advantage:60
Related articles
477600-75-2, TofacitinibRelated Search:
  • 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
  • CP 690550
  • 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-D)pyrimidin-4-yl-, (3R,4R)-
  • CP-690550(Tasocitinib,CP690550)
  • CP 690550(Tasocitinib)
  • Tasocitinib
  • 3-((3R,4R)-4-Methyl-3-(Me...
  • Tasocitinib (CP 690550)
  • 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-
  • 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-beta-oxo-, (3R,4R)-
  • Tofacitinib
  • CP-690550 Tofacitinib
  • 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropa
  • Tofaimpurity
  • Tofacitinib base
  • Tofacitinib citrate, ≥98% (HPLC)
  • CP 690550 - Tasocitinib | Tofacitinib
  • 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, Tofacitinib
  • 3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile
  • CS-344
  • CP690550 (Tofacitinib, Tasocitinib was stopped use)
  • Tofacitinib ?Tasocitinib
  • TOFACITINIB;TASOCITINIB;CP-690550;CP690550
  • Tofacitinib (CP-690550,Tasocitinib)
  • 3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)-2-oxopiperidin-1-yl)propanenitrile
  • Tropsch iMatinib
  • CP 690550 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
  • (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile
  • Tofacitinib,CP-690550
  • 477600-75-2
  • Tofacitinib, >=98%
  • 3-[4(R)-Methyl-3(R)-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]- 3-oxopropanenitrile
  • (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-2-piperidinepropanenitrile
  • 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile(CP-690550)
  • Tofacitinib (CP-690550,Tasocitinib) fandachem
  • ofacitinib
  • Tofactinib
  • Tofacitinib USP/EP/BP
  • CP-690550 DISCONTINUED
  • 477600-75-2
  • Inhibitors
  • Inhibitor